TREM1

Last updated
TREM1
Protein TREM1 PDB 1q8m.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases TREM1 , CD354, TREM-1, triggering receptor expressed on myeloid cells 1
External IDs OMIM: 605085 MGI: 1930005 HomoloGene: 10243 GeneCards: TREM1
Orthologs
SpeciesHumanMouse
Entrez

54210

58217

Ensembl

ENSG00000124731

ENSMUSG00000042265

UniProt

Q9NP99

Q9JKE2

RefSeq (mRNA)

NM_001242589
NM_001242590
NM_018643

NM_021406
NM_001347399

RefSeq (protein)

NP_001229518
NP_001229519
NP_061113

NP_001334328
NP_067381

Location (UCSC) Chr 6: 41.27 – 41.29 Mb Chr 17: 48.54 – 48.55 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily transmembrane protein that, in humans, is encoded by the TREM1 gene. [5] [6] [7] TREM1 is constitutively expressed on the surface of peripheral blood monocytes and neutrophils, and upregulated by toll-like receptor (TLR) ligands; activation of TREM1 amplifies immune responses. [6] [8] [9]

Contents

Function

Monocyte-, macrophage- and neutrophil-mediated inflammatory responses can be stimulated via receptors such as G protein-linked 7-transmembrane receptors (such as FPR1), Fc receptors, CD14, TLRs (such as TLR4), and cytokine receptors. TREM1 amplifies TLR-induced inflammation by increasing production of inflammatory cytokines. [10] The ligand of TREM1 is unknown, however, bacterial infection, ischemic stroke and challenge with lipopolysaccharide or lipoteichoic acid were observed to increase TREM1 expression. [8] In granulocytes, C/EBPε induces TREM1 expression independently from inflammatory response. [11]

TREM1 forms a complex with transmembrane adaptor DAP12 and, upon TREM1 engagement, a protein tyrosine kinase Syk-mediated cascade of tyrosine phosphorylation is initiated, activating downstream mediators such as PLCγ, PI3K, and MAPK. This cascade promotes the release of inflammatory cytokines and/or chemokines by neutrophils and macrophages, as well as their migration. [12] [13]

Based on laboratory studies, TREM1 might be involved in development of atherosclerosis, [14] non-alcoholic fatty liver disease (NAFLD), [15] and ischemic stroke. [16]

Cancer

TREM1 expression is higher in tumor vs non-tumor tissues, likely due to its expression by myeloid cells that infiltrate tumors. [17] [18] TREM1 is expressed by myeloid immune-suppressive cell populations such as monocytic myeloid-derived suppressor cells (mMDSC), tumor-associated neutrophils (TANs), and tumor associated macrophages (TAMs). These types of tumor-associated myeloid infiltrate correlate with shorter survival times of patients with solid tumors, and are likely to be the reason that not all tumors respond to checkpoint inhibitor therapy. [19] [20] Antibodies that target TREM1 are therefore being studied for use in treatment patients with tumors that do not respond to checkpoint inhibitor therapy.

Flow cytometric analyses of human tumor-infiltrating myeloid cells isolated from breast cancer, bladder cancer, endometrial cancer, head and neck squamous cell carcinoma, ovarian cancer, prostate cancer, and renal cell carcinoma tissues demonstrated that within tumors, TREM1 is enriched on myeloid subsets, including mMDSCs, TANs, TAMs (AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021 abstract no. P104). Single-cell immune profiling of stage III-C ovarian tumor specimens revealed that TREM1 is specifically expressed in TAM and monocytes in these tumors (AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2019 abstract no. C105). Additional studies found high expression of TREM1 protein and TREM1 mRNA, respectively, in TAMs and monocytes in human tumors (Immunotherapy of Cancer Conference (ITOC) 2021 Abstract P02.11, Society for the Immunotherapy of Cancer (SITC) Conference 2021, Poster 859).

Higher levels of TREM1 mRNA in tumor tissues correlate with shorter survival times of patients with colon cancer, breast cancer, pancreatic cancer, and squamous cell carcinoma (AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2019 abstract no. C105).

Soluble TREM1

During inflammation, a soluble form of the molecule (sTREM1) accumulates in the circulation, and is a biomarker of inflammation. There is debate over whether sTREM1 is produced as a splice variant or as the results of proteolytic cleavage. [21] [22] sTREM1 acts as a decoy for the unknown TREM1 ligands, and thereby prevents TREM1 activation. [23] sTREM1 has been studied as a biomarker of development of pneumonia, sepsis, [24] inflammatory bowel diseases, [25] [26] and liver cirrhosis. [27]

Model organisms

Model organisms have been used in the study of TREM1 function. A conditional knockout mouse line called Trem1tm1(KOMP)Vlcg was generated at the Wellcome Trust Sanger Institute. [28] Male and female animals underwent a standardized phenotypic screen [29] to determine the effects of deletion. [30] [31] [32] [33] Additional screens included immune phenotyping. [34] Blockade of TREM1 protects mice against microbe-induced shock, indicating that it is an important regulator of the immune response. [8]

TREM1 as a Therapeutic Target

Pionyr Immunotherapeutics is developing PY159 for treatment of advanced solid tumors refractory to or relapsed with the current standard of care. PY159 is a humanized monoclonal antibody that binds TREM1 and acts as an agonist, crosslinking TREM1 to induce signaling through the TREM1-DAP12 complex (SITC 2019 Poster P812, AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2019 abstract no. C-105, AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021 Abstract P104, ITOC 2021 Abstract P02.11, SITC 2021 Poster 859). PY159 is being evaluated in a phase 1 trial, in combination with pembrolizumab, in subjects with advanced solid tumors

Celsius Therapeutics is developing CEL383, an antibody inhibitor of TREM1, for treatment of inflammatory bowel disease. As of October 2023, CEL383 is being evaluated in a phase 1 trial in healthy volunteers.


Related Research Articles

<span class="mw-page-title-main">Interleukin 10</span> Anti-inflammatory cytokine

Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. In humans, interleukin 10 is encoded by the IL10 gene. IL-10 signals through a receptor complex consisting of two IL-10 receptor-1 and two IL-10 receptor-2 proteins. Consequently, the functional receptor consists of four IL-10 receptor molecules. IL-10 binding induces STAT3 signalling via the phosphorylation of the cytoplasmic tails of IL-10 receptor 1 + IL-10 receptor 2 by JAK1 and Tyk2 respectively.

<span class="mw-page-title-main">Complement component 5a</span> Protein fragment

C5a is a protein fragment released from cleavage of complement component C5 by protease C5-convertase into C5a and C5b fragments. C5b is important in late events of the complement cascade, an orderly series of reactions which coordinates several basic defense mechanisms, including formation of the membrane attack complex (MAC), one of the most basic weapons of the innate immune system, formed as an automatic response to intrusions from foreign particles and microbial invaders. It essentially pokes microscopic pinholes in these foreign objects, causing loss of water and sometimes death. C5a, the other cleavage product of C5, acts as a highly inflammatory peptide, encouraging complement activation, formation of the MAC, attraction of innate immune cells, and histamine release involved in allergic responses. The origin of C5 is in the hepatocyte, but its synthesis can also be found in macrophages, where it may cause local increase of C5a. C5a is a chemotactic agent and an anaphylatoxin; it is essential in the innate immunity but it is also linked with the adaptive immunity. The increased production of C5a is connected with a number of inflammatory diseases.

<span class="mw-page-title-main">CD80</span> Mammalian protein found in Homo sapiens

The Cluster of differentiation 80 is a B7, type I membrane protein in the immunoglobulin superfamily, with an extracellular immunoglobulin constant-like domain and a variable-like domain required for receptor binding. It is closely related to CD86, another B7 protein (B7-2), and often works in tandem. Both CD80 and CD86 interact with costimulatory receptors CD28, CTLA-4 (CD152) and the p75 neurotrophin receptor.

<span class="mw-page-title-main">CCL7</span> Mammalian protein found in Homo sapiens

Chemokine ligand 7 (CCL7) is a small cytokine that was previously called monocyte-chemotactic protein 3 (MCP3). CCL7 is a small protein that belongs to the CC chemokine family and is most closely related to CCL2.

CD16, also known as FcγRIII, is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophils, monocytes, macrophages, and certain T cells. CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b), which participate in signal transduction. The most well-researched membrane receptor implicated in triggering lysis by NK cells, CD16 is a molecule of the immunoglobulin superfamily (IgSF) involved in antibody-dependent cellular cytotoxicity (ADCC). It can be used to isolate populations of specific immune cells through fluorescent-activated cell sorting (FACS) or magnetic-activated cell sorting, using antibodies directed towards CD16.

Macrophage-1 antigen is a complement receptor ("CR3") consisting of CD11b and CD18.

<span class="mw-page-title-main">Toll-like receptor 10</span> Protein-coding gene in the species Homo sapiens

Toll-like receptor 10 is a protein that in humans is encoded by the TLR10 gene. TLR10 has also been designated as CD290 . TLR10 has not been extensively studied because it is a pseudogene in mice, though all other mammalian species contain an intact copy of the TLR10 gene. Unlike other TLRs, TLR10 does not activate the immune system and has instead been shown to suppress inflammatory signaling on primary human cells. This makes TLR10 unique among the TLR family. TLR10 was thought to be an "orphan" receptor, however, recent studies have identified ligands for TLR10 and these include HIV-gp41. Ligands for TLR2 are potential ligands for TLR10.

<span class="mw-page-title-main">PD-L1</span> Mammalian protein found in Homo sapiens

Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene.

<span class="mw-page-title-main">Formyl peptide receptor 2</span> Protein-coding gene in the species Homo sapiens

N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) located on the surface of many cell types of various animal species. The human receptor protein is encoded by the FPR2 gene and is activated to regulate cell function by binding any one of a wide variety of ligands including not only certain N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP) but also the polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). Because of its interaction with lipoxin A4, FPR2 is also commonly named the ALX/FPR2 or just ALX receptor.

<span class="mw-page-title-main">TYROBP</span> Protein-coding gene in the species Homo sapiens

TYRO protein tyrosine kinase-binding protein is an adapter protein that in humans is encoded by the TYROBP gene.

<span class="mw-page-title-main">CD244</span> Protein found in humans

CD244 also known as 2B4 or SLAMF4 is a protein that in humans is encoded by the CD244 gene.

<span class="mw-page-title-main">Vascular endothelial growth inhibitor</span> Protein-coding gene in the species Homo sapiens

Vascular endothelial growth inhibitor (VEGI), also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15 (TNFSF15), is protein that in humans is encoded by the TNFSF15 gene. VEGI is an anti-angiogenic protein. It belongs to tumor necrosis factor (ligand) superfamily, where it is member 15. It is the sole known ligand for death receptor 3, and it can also be recognized by decoy receptor 3.

<span class="mw-page-title-main">CD200</span> Protein-coding gene in the species Homo sapiens

OX-2 membrane glycoprotein, also named CD200 is a human protein encoded by the CD200 gene. CD200 gene is in human located on chromosome 3 in proximity to genes encoding other B7 proteins CD80/CD86. In mice CD200 gene is on chromosome 16.

<span class="mw-page-title-main">MARCO</span> Protein-coding gene in the species Homo sapiens

Macrophage receptor with collagenous structure (MARCO) is a protein that in humans is encoded by the MARCO gene. MARCO is a class A scavenger receptor that is found on particular subsets of macrophages. Scavenger receptors are pattern recognition receptors (PRRs) found most commonly on immune cells. Their defining feature is that they bind to polyanions and modified forms of a type of cholesterol called low-density lipoprotein (LDL). MARCO is able to bind and phagocytose these ligands and pathogen-associated molecular patterns (PAMPs), leading to the clearance of pathogens and cell signaling events that lead to inflammation. As part of the innate immune system, MARCO clears, or scavenges, pathogens, which leads to inflammatory responses. The scavenger receptor cysteine-rich (SRCR) domain at the end of the extracellular side of MARCO binds ligands to activate the subsequent immune responses. MARCO expression on macrophages has been associated with tumor development and also with Alzheimer's disease, via decreased responses of cells when ligands bind to MARCO.

<span class="mw-page-title-main">Peptidoglycan recognition protein 1</span> Protein-coding gene in the species Homo sapiens

Peptidoglycan recognition protein 1, PGLYRP1, also known as TAG7, is an antibacterial and pro-inflammatory innate immunity protein that in humans is encoded by the PGLYRP1 gene.

<span class="mw-page-title-main">TREM2</span> Protein-coding gene in the species Homo sapiens

Triggering receptor expressed on myeloid cells 2(TREM2) is a protein that in humans is encoded by the TREM2 gene. TREM2 is expressed on macrophages, immature monocyte-derived dendritic cells, osteoclasts, and microglia, which are immune cells in the central nervous system. In the liver, TREM2 is expressed by several cell types, including macrophages, that respond to injury. In the intestine, TREM2 is expressed by myeloid-derived dendritic cells and macrophage. TREM2 is overexpressed in many tumor types and has anti-inflammatory activities. It might therefore be a good therapeutic target.

<span class="mw-page-title-main">FCAR</span> Mammalian protein found in Homo sapiens

Fc fragment of IgA receptor (FCAR) is a human gene that codes for the transmembrane receptor FcαRI, also known as CD89. FcαRI binds the heavy-chain constant region of Immunoglobulin A (IgA) antibodies. FcαRI is present on the cell surface of myeloid lineage cells, including neutrophils, monocytes, macrophages, and eosinophils, though it is notably absent from intestinal macrophages and does not appear on mast cells. FcαRI plays a role in both pro- and anti-inflammatory responses depending on the state of IgA bound. Inside-out signaling primes FcαRI in order for it to bind its ligand, while outside-in signaling caused by ligand binding depends on FcαRI association with the Fc receptor gamma chain.

<span class="mw-page-title-main">IL17A</span> Protein-coding gene in the species Homo sapiens

Interleukin-17A is a protein that in humans is encoded by the IL17A gene. In rodents, IL-17A used to be referred to as CTLA8, after the similarity with a viral gene.

Chemorepulsion is the directional movement of a cell away from a substance. Of the two directional varieties of chemotaxis, chemoattraction has been studied to a much greater extent. Only recently have the key components of the chemorepulsive pathway been elucidated. The exact mechanism is still being investigated, and its constituents are currently being explored as likely candidates for immunotherapies.

Nangibotide is an inhibitor of TREM-1, a receptor found on certain white blood cells. Activation of TREM-1 stimulates inflammation. Nangibotide is therefore being investigated as a treatment for the overwhelming inflammation typically seen in severe sepsis.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000124731 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000042265 - Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Gingras MC, Lapillonne H, Margolin JF (March 2002). "TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development". Molecular Immunology. 38 (11): 817–24. doi:10.1016/S0161-5890(02)00004-4. PMID   11922939.
  6. 1 2 Bouchon A, Dietrich J, Colonna M (May 2000). "Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes". Journal of Immunology. 164 (10): 4991–5. doi: 10.4049/jimmunol.164.10.4991 . PMID   10799849.
  7. ↑ "Entrez Gene: TREM1 triggering receptor expressed on myeloid cells 1".
  8. 1 2 3 Bouchon A, Facchetti F, Weigand MA, Colonna M (April 2001). "TREM-1 amplifies inflammation and is a crucial mediator of septic shock". Nature. 410 (6832): 1103–7. doi:10.1038/35074114. PMID   11323674. S2CID   4403589.
  9. ↑ Mabbott, Neil A; Baillie, J; Brown, Helen; Freeman, Tom C; Hume, David A (2013). "An expression atlas of human primary cells: inference of gene function from coexpression networks". BMC Genomics. 14 (1): 632. doi: 10.1186/1471-2164-14-632 . ISSN   1471-2164. PMC   3849585 . PMID   24053356.
  10. ↑ Arts RJ, Joosten LA, van der Meer JW, Netea MG (February 2013). "TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors". Journal of Leukocyte Biology. 93 (2): 209–15. doi: 10.1189/jlb.0312145 . PMID   23108097.
  11. ↑ Suh HC, Benoukraf T, Shyamsunder P, Yin T, Cao Q, Said J, et al. (April 2017). "LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBPε in granulocytes". Scientific Reports. 7: 46440. Bibcode:2017NatSR...746440S. doi:10.1038/srep46440. PMC   5404328 . PMID   28440307.
  12. ↑ Niu, Zhiyuan; Shi, Qian; Zhang, Wenlong; Shu, Yuxin; Yang, Nanfei; Chen, Bing; Wang, Qingsong; Zhao, Xuyang; Chen, Jiajia; Cheng, Nan; Feng, Xiujing (December 2017). "Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs". Nature Communications. 8 (1): 766. Bibcode:2017NatCo...8..766N. doi:10.1038/s41467-017-00523-6. ISSN   2041-1723. PMC   5626701 . PMID   28974683.
  13. ↑ Tammaro, Alessandra; Derive, Marc; Gibot, Sebastien; Leemans, Jaklien C.; Florquin, Sandrine; Dessing, Mark C. (2017-09-01). "TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives". Pharmacology & Therapeutics. 177: 81–95. doi: 10.1016/j.pharmthera.2017.02.043 . ISSN   0163-7258. PMID   28245991. S2CID   19380728.
  14. ↑ Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, et al. (October 2016). "TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis". Nature Communications. 7 (1): 13151. Bibcode:2016NatCo...713151Z. doi:10.1038/ncomms13151. PMC   5080444 . PMID   27762264.
  15. ↑ Rao S, Huang J, Shen Z, Xiang C, Zhang M, Lu X (February 2019). "Inhibition of TREM-1 attenuates inflammation and lipid accumulation in diet-induced nonalcoholic fatty liver disease". Journal of Cellular Biochemistry. 120 (7): 11867–11877. doi:10.1002/jcb.28468. PMC   6593463 . PMID   30805986.
  16. ↑ Tammaro, Alessandra; Derive, Marc; Gibot, Sebastien; Leemans, Jaklien C.; Florquin, Sandrine; Dessing, Mark C. (September 2017). "TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives". Pharmacology & Therapeutics. 177: 81–95. doi: 10.1016/j.pharmthera.2017.02.043 . PMID   28245991. S2CID   19380728.
  17. ↑ Broz, Miranda L.; Binnewies, Mikhail; Boldajipour, Bijan; Nelson, Amanda E.; Pollack, Joshua L.; Erle, David J.; Barczak, Andrea; Rosenblum, Michael D.; Daud, Adil; Barber, Diane L.; Amigorena, Sebastian (November 2014). "Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity". Cancer Cell. 26 (5): 638–652. doi:10.1016/j.ccell.2014.09.007. PMC   4254577 . PMID   25446897.
  18. ↑ Lavin, Yonit; Kobayashi, Soma; Leader, Andrew; Amir, El-ad David; Elefant, Naama; Bigenwald, Camille; Remark, Romain; Sweeney, Robert; Becker, Christian D.; Levine, Jacob H.; Meinhof, Klaus (May 2017). "Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses". Cell. 169 (4): 750–765.e17. doi:10.1016/j.cell.2017.04.014. PMC   5737939 . PMID   28475900.
  19. ↑ Awad, Robin Maximilian; De Vlaeminck, Yannick; Maebe, Johannes; Goyvaerts, Cleo; Breckpot, Karine (2018-08-31). "Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression". Frontiers in Immunology. 9: 1977. doi: 10.3389/fimmu.2018.01977 . ISSN   1664-3224. PMC   6127274 . PMID   30233579.
  20. ↑ Bingle, L.; Brown, N. J.; Lewis, C. E. (March 2002). "The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies". The Journal of Pathology. 196 (3): 254–265. doi: 10.1002/path.1027 . ISSN   0022-3417. PMID   11857487. S2CID   8481685.
  21. ↑ Baruah S, Keck K, Vrenios M, Pope MR, Pearl M, Doerschug K, Klesney-Tait J (December 2015). "Identification of a Novel Splice Variant Isoform of TREM-1 in Human Neutrophil Granules". Journal of Immunology. 195 (12): 5725–31. doi:10.4049/jimmunol.1402713. PMC   4670805 . PMID   26561551.
  22. ↑ Gómez-Piña V, Soares-Schanoski A, Rodríguez-Rojas A, Del Fresno C, García F, Vallejo-Cremades MT, et al. (September 2007). "Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes". Journal of Immunology. 179 (6): 4065–73. doi: 10.4049/jimmunol.179.6.4065 . PMID   17785845.
  23. ↑ Gibot S, Kolopp-Sarda MN, Béné MC, Bollaert PE, Lozniewski A, Mory F, et al. (December 2004). "A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis". The Journal of Experimental Medicine. 200 (11): 1419–26. doi:10.1084/jem.20040708. PMC   2211948 . PMID   15557347.
  24. ↑ Tejera A, Santolaria F, Diez ML, Alemán-Valls MR, González-Reimers E, Martínez-Riera A, Milena-Abril A (June 2007). "Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response". Cytokine. 38 (3): 117–23. doi:10.1016/j.cyto.2007.05.002. PMID   17659879.
  25. ↑ Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, et al. (July 2009). "Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease". Digestive Diseases and Sciences. 54 (7): 1525–31. doi:10.1007/s10620-008-0514-5. PMID   18975078. S2CID   12356021.
  26. ↑ Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, Kim WH, Cheon JH (November 2012). "Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases". Digestive and Liver Disease. 44 (11): 897–903. doi:10.1016/j.dld.2012.05.011. PMID   22721842.
  27. ↑ Tornai D, Vitalis Z, Jonas A, Janka T, Foldi I, Tornai T, et al. (March 2021). "Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality". Clinics and Research in Hepatology and Gastroenterology. 45 (5): 101579. doi: 10.1016/j.clinre.2020.11.009 . PMID   33773436.
  28. ↑ Gerdin AK (2010). "The Sanger Mouse Genetics Programme: high throughput characterisation of knockout mice". Acta Ophthalmologica. 88: 925–7. doi:10.1111/j.1755-3768.2010.4142.x. S2CID   85911512.
  29. ↑ "International Mouse Phenotyping Consortium".
  30. ↑ Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. (June 2011). "A conditional knockout resource for the genome-wide study of mouse gene function". Nature. 474 (7351): 337–42. doi:10.1038/nature10163. PMC   3572410 . PMID   21677750.
  31. ↑ Dolgin E (June 2011). "Mouse library set to be knockout". Nature. 474 (7351): 262–3. doi: 10.1038/474262a . PMID   21677718.
  32. ↑ Collins FS, Rossant J, Wurst W (January 2007). "A mouse for all reasons". Cell. 128 (1): 9–13. doi: 10.1016/j.cell.2006.12.018 . PMID   17218247. S2CID   18872015.
  33. ↑ White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, et al. (July 2013). "Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes". Cell. 154 (2): 452–64. doi:10.1016/j.cell.2013.06.022. PMC   3717207 . PMID   23870131.
  34. ↑ "Infection and Immunity Immunophenotyping (3i) Consortium".

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.